Can you discover "Broadly Neutralizing Antibodies" that cover multiple viral variants?

Yes. To target conserved epitopes across different strains (e.g., Influenza or Coronaviruses), we employ a Sequential or Mixed Panning Strategy. By alternating the selection process between different viral variants or using a cocktail of antigens, we can pressure the library to yield antibodies that recognize shared, non-mutating domains.

Is the service compatible with challenging antigens like membrane-bound viral glycoproteins?

Absolutely. Many infectious disease targets are complex, multi-pass membrane proteins. We utilize Yeast Display in conjunction with Virus-Like Particles (VLPs) or stable cell lines to present the antigen in its native, trimeric, or glycosylated state. This ensures that the discovered antibodies can recognize the pathogen in a real-world physiological environment.

Do you perform neutralization assays or only binding assays?

While our primary service is antibody discovery, we provide integrated In Vitro Neutralization Assays using viruses or recombinant toxins. We can assess the antibody's ability to block receptor binding (e.g., ACE2 blocking) or inhibit viral entry, providing you with functional data beyond simple KD values.

Infectious Disease Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

In the race against infectious diseases, the need for fast, high-quality antibody candidates is more critical than ever. At Creative Biolabs, we combine our premier human antibody libraries with expert functional screening to deliver developable, high-affinity antibodies with speed and precision reducing timelines, mitigating risks, and driving faster progress to preclinical studies.

Get Started - Request Your Quote Today

Anti-Infectious Disease-Specific Antibody Discovery

At Creative Biolabs, our screening platform is a strategic engine designed to deliver robust, developable antibodies for infectious disease targets. Our advanced phage display and yeast display technologies provide unparalleled diversity, while our multi-parameter panning strategies ensure only the most functional candidates emerge.

We navigate vast libraries with precision to identify the best leads by implementing early-stage de-risking. This process proactively addresses critical challenges such as low-affinity hits, non-specific binders, epitope redundancy, and the common trade-offs between function and affinity. This strategic approach results in a faster, more reliable progression to MoA validation and preclinical studies, reducing the need for costly re-engineering cycles.

Speak with an Expert and Get Pricing

Workflow

Discovery Design & Antigen Strategy

Target assessment; antigen format optimization (VLP, recombinant spike, or toxin); cross-reactivity planning for variants; decoy strategy for host homologues.
Biopanning & Enrichment

Up to 4 rounds of competitive/subtractive panning; blocking strategies to target cryptic epitopes; epitope masking; high-stringency washing for off-rate selection.
Single-Clone Screening & Specificity De-risking

High-throughput validation; orthogonal specificity checks against host proteome; early specificity and non-specific binding (NSB) triage. Ranked clone list with specificity profiles.
Functional Selection & Epitope Strategy

Surrogate neutralization assays (e.g., blocking); epitope binning to ensure diversity; cross-strain reactivity checks.
Sequence Analytics & Liability Filtering

NGS-driven clonotype clustering; in silico liability screens; framework optimization paths.
Expression, IgG Conversion & Developability Panel

Mini-panel IgG expression; biophysics profiling (solubility, stability, aggregation propensity).

Take the Next Step. Request Your Quote Today.

Ready-to-Screen Antibody Libraries

Choose from our diverse selection of premade antibody libraries, each engineered for optimal performance in infectious disease discovery. Whether you're targeting viral, bacterial, or other pathogens, we provide the perfect framework to accelerate your program.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study

Case 1: Rapid Discovery of High-Affinity scFv Antibodies Against a Viral Variant

Objective

The rapid evolution of viral pathogens demands an antibody discovery platform that is both fast and precise. For infectious disease research, neutralizing antibodies must be identified quickly to keep pace with viral mutations that may evade previous immune responses. This case study demonstrates our success in using a Premade Synthetic Human scFv Library to isolate a diverse panel of antibodies against a specific, high-priority viral variant. By bypassing animal immunization, we compressed the discovery timeline, delivering high-quality leads ready for neutralization assays.

Project Strategy

To address the urgency of infectious disease research, we implemented an optimized In-solution Phage Display workflow.

Target: A purified recombinant variant of a viral surface glycoprotein (Spike protein variant).
Library: Our proprietary Premade Human scFv Library, featuring high functional diversity and optimized human frameworks to minimize immunogenicity.

Selection Workflow:

High-Stringency Panning
Three to four rounds of in-solution selection were performed to ensure the capture of high-affinity binders.

Variant Focus
The screening conditions were fine-tuned to prioritize clones that recognize the unique conformational epitopes of the variant.

High-Throughput Identification
Large-scale monoclonal screening was conducted post-panning to maximize the recovery of unique sequences.

Key Results & Data Validation

1. Robust Library Enrichment
The selection process yielded a dramatic increase in phage recovery rates, particularly between Round 1 and Round 3. This exponential enrichment indicates a highly successful convergence toward variant-specific binders.
2. Validation of Binding via Soluble ELISA
Post-identification, more than 10 unique scFv clones were confirmed as positive binders. Validation via Soluble ELISA demonstrated that these candidates possess high binding intensity, providing a robust pool of leads for downstream virus neutralization and therapeutic characterization.

Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Enrichment Kinetics Against the Viral Variant. The "Output/Input" ratio demonstrates strong selection pressure and successful library convergence, ensuring a high hit rate of positive clones.

Fig.8 Graph displaying the binding validation results. (Creative Biolabs Original)

Specificity Validation of Lead scFv Candidates. Soluble ELISA results confirm that the identified clones exhibit strong binding to the target viral variant, with minimal background noise.

Case 2: Rapid Discovery of High-Affinity scFv Antibodies Against a Viral Variant
Objective	Bacterial exotoxins are among the most potent poisons known and are primary virulence factors in many infectious diseases. However, developing antibodies against them is fraught with challenges: their extreme toxicity often makes animal immunization lethal, and their complex structures are frequently prone to aggregation or denaturation during traditional screening processes. This case study demonstrates how we leveraged our Premade Human scFv Antibody Library to bypass the toxicity barrier and isolate high-affinity, conformationally specific antibodies that neutralize a lethal toxin.
Project Strategy	To address target toxicity and instability, we employed a dual-stage subtractive screening strategy designed for functional relevance: Precision Epitope Filtering Negative selection against denatured variants eliminates "dead-end" binders to non-functional fragments. Native-State Preservation In-solution panning maintains the toxin's bioactive 3D conformation, avoiding surface-induced denaturation.
Key Results & Functional Validation	1. High-Precision Specificity Profile The screening successfully yielded clones that are highly sensitive to the toxin's native fold. Soluble ELISA validation confirmed that the lead candidates bind exclusively to the functional toxin, with zero cross-reactivity to the denatured control. ELISA results show that the lead Fab clones distinguish between the native toxin and the denatured form, ensuring the antibodies target the biologically active protein.

Start Your Journey. Request Your Quote Today.

Related Services

Fig.10 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-tumor-specific Target Antibody Discovery

Anti-inflammation disease-specific Antibody Discovery

Anti-autoimmune disorder-specific Antibody Discovery

Anti-allograft rejection-specific Antibody Discovery

Why Choose Us?

Function-First Selection

We go beyond simple binding to identify functional leads that align perfectly with your specific Mechanism of Action (MoA). Our screening process filters for neutralizing activity and protective efficacy from the earliest stages.

Safety and Unrestricted Targeting

By bypassing animal immunization, we safely target highly pathogenic toxins and viral antigens that would otherwise be lethal or non-immunogenic in vivo. This allows us to work with the most challenging infectious agents without biological constraints.

Adaptive Solutions for Viral Evolution

Our platform is specifically tuned to handle rapidly mutating targets. This makes Creative Biolabs an ideal partner for pandemic preparedness, allowing for the quick generation of antibody variants to counter viral escape mutants.

Superior Diversity for Rare Epitopes

Our platform captures a vast repertoire of human scFv clones. This increases the probability of identifying rare neutralizing epitopes that are often missed by conventional discovery methods.

Customize Your Package. Get Pricing.

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Can you discover "Broadly Neutralizing Antibodies" that cover multiple viral variants?
Yes. To target conserved epitopes across different strains (e.g., Influenza or Coronaviruses), we employ a Sequential or Mixed Panning Strategy. By alternating the selection process between different viral variants or using a cocktail of antigens, we can pressure the library to yield antibodies that recognize shared, non-mutating domains.
Is the service compatible with challenging antigens like membrane-bound viral glycoproteins?
Absolutely. Many infectious disease targets are complex, multi-pass membrane proteins. We utilize Yeast Display in conjunction with Virus-Like Particles (VLPs) or stable cell lines to present the antigen in its native, trimeric, or glycosylated state. This ensures that the discovered antibodies can recognize the pathogen in a real-world physiological environment.
Do you perform neutralization assays or only binding assays?
While our primary service is antibody discovery, we provide integrated In Vitro Neutralization Assays using viruses or recombinant toxins. We can assess the antibody's ability to block receptor binding (e.g., ACE2 blocking) or inhibit viral entry, providing you with functional data beyond simple K_D values.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: